Place des alphabloquants chez la femme : revue de la littérature
| Autor: | L. Hoquetis, S. Larre, F. Taha |
|---|---|
| Přispěvatelé: | Service d'urologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
education.field_of_study business.industry Urology [SDV]Life Sciences [q-bio] Population Urinary bladder neck obstruction 030232 urology & nephrology Urination disorder urologic and male genital diseases medicine.disease Placebo Urinary tract disorder 3. Good health 03 medical and health sciences Bladder outlet obstruction 0302 clinical medicine Overactive bladder Medicine business education Voiding Disorders |
| Zdroj: | Progrès en Urologie Progrès en Urologie, Elsevier Masson, 2020, 30, pp.1078-1095. ⟨10.1016/j.purol.2020.06.006⟩ |
| ISSN: | 1166-7087 |
| DOI: | 10.1016/j.purol.2020.06.006⟩ |
| Popis: | INTRODUCTION Marketing authorization of alphablockers is limited principally to men with benign hypertrophy of prostate. The objective of this review is to evaluate clinical and urodynamic improvement of alphablockers in women. METHOD A review of the literature was carried out on all prospective studies about the use of alphablockers in women with urination disorders. RESULTS Seventeen articles have been included. The selected articles were classified according to the studied population: lower urinary tract disorders, bladder emptying disorders without details on mechanism, bladder outlet obstruction, detrusor hypoactivity overactive bladder. Four studies were randomized against placebo. There was an improvement in the IPSS in 8 studies going as far as a decrease of 11,7 points (4.6 vs. 16.3 P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|